Recently, Roche Laboratories, the maker of Tamiflu, revised the package insert of the flu drug. The new insert describes neuropsychiatric events that have been reported in patients using Tamiflu. There have been reports of self-injury and delirium with the use of Tamiflu, particularly in children. Roche recommends that patients with the flu, who have been treated with Tamiflu, be closely monitored for signs of abnormal behavior.
Comments are closed.